Showing results (91-100 of 183) with videos related to
Sort By:
Pageof 19
NPJ Breast Cancer|May 14, 2026
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41Ilana Schlam, Gong Tang, Khalid AbdulJabbar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsAntoinette R Tan, Donna Headlee, Richard Messmann, et al.Cancers|April 3, 2021
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low, Suparna B Wedam, James J Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox, Jennifer Low, James Lee, et al.Radiology|August 22, 2007
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experienceArpi Thukral, David M Thomasson, Catherine K Chow, et al.Research Square|August 26, 2024
Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients with Metastatic Breast Cancer: The LEANORA studySandra Swain, Ilana Schlam, D Max Smith, et al.European Journal of Cancer (Oxford, England : 1990)|November 21, 2022
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerSandra M Swain, Antoinette R Tan, Luca Gianni, et al.Journal of the National Cancer Institute|March 15, 2011
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCISIrene L Wapnir, James J Dignam, Bernard Fisher, et al.Journal of Clinical Epidemiology|January 14, 2024
Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluationAshley M Hopkins, Natansh D Modi, Frank W Rockhold, et al.Pageof 19